The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC) is dedicated to research and education in cancer and related disorders and to the prompt application of new knowledge to the treatment of patients and to the prevention of neoplastic diseases. This application requests continued CCSG support for SKCCC's research programs and shared resources. The SKCCC is a multi-disciplinary, interdepartmental center of the Johns Hopkins University. There is a broad base of ongoing cancer research at Johns Hopkins. The special scientific programs of the Cancer Center are interdisciplinary in character and are focused on human disease. A wide range of activity is encompassed ranging from fundamental research into the molecular genetics of human tumorigenesis to clinical trials of new antitumor treatments. The Cancer Center has established twelve major research programs: Cancer Biology (Baylin, Velculescu), Hematologic Malignancies and BMT (Ambinder, Jones), Cancer Immunology (Pardoll), Viral Oncology (Hayward, Roden), Cancer Prevention and Control (Groopman, Platz), Chemical Therapeutics (Cole), Prostate Cancer (Carducci, Getzenberg), Breast Cancer (Stearns, Sukumar), Gastrointestinal Cancer (Jaffee, Kern) Upper Aerodigestive Cancer (Rudin, Sidransky), Brain Cancer (Grossman, Brem, Laterra), and Cancer Molecular &Functional Imaging (Bhujwalla, Pomper). Twenty-two Shared Resources support the needs of Cancer Center investigators: Animal Resources, Bioinformatics, Microarray, Cancer Functional Imaging, Cell Imaging, Common Equipment, Cytogenetics, Experimental Irradiators, Flow Cytometry, Glassware Washing, Mass Spectrometry, Specimen Accessioning Core (SAC), Tissue Microarray Core, Pharmacology Analytical Core, Human Immunology, Cell Processing and Gene Therapy, Cellular Therapy (GEL),Biostatistics, Research Pharmacy, Next Generation Sequencing, Image Response Assessment the Clinical Research Office.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-50
Application #
8527721
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1997-05-07
Project End
2017-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
50
Fiscal Year
2013
Total Cost
$6,540,575
Indirect Cost
$2,503,183
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151

Showing the most recent 10 out of 2393 publications